Literature DB >> 7508488

Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection.

N Sakamoto1, N Enomoto, M Kurosaki, F Marumo, C Sato.   

Abstract

Hepatitis C virus (HCV) infection is characterized by persistence of liver inflammation that often leads to end-stage liver disease, although the mechanisms are not fully understood. A hypervariable region (HVR) has been reported in the E2/NS1 region of the HCV genome, in which striking diversity is found among different HCV isolates. To investigate the association of the HVR alterations with the clinical courses of HCV infection, a longitudinal analysis of the HVR in patients with acute HCV infection was carried out. Plasma samples were obtained at several times in three patients with acute hepatitis C. Plasma RNA was extracted and reverse transcribed, and DNA fragments that included the HVR were amplified by PCR. The sequences of the HVR were directly determined from the PCR products by the dideoxy chain termination method, from which amino acid sequences were deduced. In all cases, plasma HCV-RNA disappeared with the improvement of the initial alanine aminotransferase (ALT) elevation, but HCV-RNA reappeared about 1 year later with or without deterioration of the hepatitis. In a case of sporadic acute hepatitis, the HCV in the recurrent phase had seven amino acid substitutions in the HVR compared with that in the acute phase, although no amino acid changes were noted during the initial acute phase. In a case of posttransfusion hepatitis, a marked difference was observed between the acute and the recurrent phases, with an amino acid homology of 30% (8/27). The mutation rate of the HVR had a tendency to accelerate as the HCV infection progressed to the chronic stage.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7508488     DOI: 10.1002/jmv.1890420119

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.

Authors:  J McAllister; C Casino; F Davidson; J Power; E Lawlor; P L Yap; P Simmonds; D B Smith
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 2.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters.

Authors:  J P Allain; Y Dong; A M Vandamme; V Moulton; M Salemi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

7.  Lymphocyte and macrophage phenotypes in chronic hepatitis C infection. Correlation with disease activity.

Authors:  S I Khakoo; P N Soni; K Savage; D Brown; A P Dhillon; L W Poulter; G M Dusheiko
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

8.  Genetic evolution of structural region of hepatitis C virus in primary infection.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Variations in the core region of hepatitis C virus genomes in patients with chronic hepatitis.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 10.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.